Cargando…
Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311
C1311 is a novel therapeutic agent with potent activity against experimental colorectal cancer that has been selected for entry into clinical trial. The compound has previously been shown to have DNA-binding properties and to inhibit the catalytic activity of topoisomerase II. In this study, cellula...
Autores principales: | Burger, A M, Jenkins, T C, Double, J A, Bibby, M C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362878/ https://www.ncbi.nlm.nih.gov/pubmed/10496367 http://dx.doi.org/10.1038/sj.bjc.6690702 |
Ejemplares similares
-
Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation.
por: Lamb, J., et al.
Publicado: (1996) -
Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.
por: Burger, A. M., et al.
Publicado: (1996) -
Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells
por: Niemira, Magdalena, et al.
Publicado: (2020) -
The imidazoacridinone C-1311 induces p53-dependent senescence or p53-independent apoptosis and sensitizes cancer cells to radiation
por: Skwarska, Anna, et al.
Publicado: (2017) -
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
por: Patterson, L H, et al.
Publicado: (2000)